Clinical Trials Plenary Session
| Event Time: | Tuesday May 7, 2019 9:15 am to 11:30 am |
| Topic(s): | Aging, Dementia, Cognitive, and Behavioral Neurology, MS and CNS Inflammatory Disease, General Neurology, Headache, Neuromuscular and Clinical Neurophysiology (EMG), Autoimmune Neurology, Neuro-oncology, Neuro Trauma, Critical Care, and Sports Neurology |
| Director(s): | Deborah Hall MD, PhD, FAAN, Holly Hinson MD, MCR, FAAN |
| Description: | This session covers important clinical topics identified from other society meetings that affect patient care. The latest updates within several clinical trials conducted over the course of the last year will be presented. |
| Completion Message: | |
| CME Credits: | 2.25 |
| Core Competencies: |
| Start/End Time | Title | Faculty |
|---|---|---|
| 9:15 AM - 9:30 AM | SPRINT MIND: Results Update and Future Directions | Jeff D. Williamson |
| 9:30 AM - 9:45 AM | Randomized Controlled Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder | Bruce A. C. Cree MD, PhD, MCR, FAAN |
| 9:45 AM - 10:00 AM | Intravenous Immunoglobulin to prevent Myasthenic Crisis after Thymectomy and other Surgical Procedures can be omitted: A Randomized, Controlled, Double-Blind Trial | Josep Gamez MD, PhD |
| 10:00 AM - 10:15 AM | rAAV2/2-ND4 for the Treatment of LHON: 72-week Data from the REVERSE Phase III Clinical Trial | Mark L. Moster MD, FAAN |
| 10:15 AM - 10:30 AM | A Placebo-Controlled Study of Galcanezumab in Patients with Episodic Cluster Headache: Results from the 8-Week Double-Blind Treatment Phase | David W. Dodick MD, FAAN |
| 10:30 AM - 10:45 AM | Use of Tranexamic Acid in Patients with Traumatic Brain Injury: Results from the North American Multi-Center Prehospital TXA for TBI Trial | Susan Rowell MD, MCR |
| 10:45 AM - 11:00 AM | From Bench to Bedside to Beam: Hippocampal-sparing during Brain Irradiation | Vinai Gondi |
| 11:00 AM - 11:15 AM | A Phase 3 Study of Isradipine as a Disease Modifying Agent in Patients with Early Parkinson’s disease (STEADY-PD III): Final Study Results | Tanya Simuni MD |
| Speaker | Disclosure |
|---|---|
| Bruce A. C. Cree, MD, PhD, MCR, FAAN | Dr. Cree has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, Akili, Alexion, Biogen, EMD Serono, Novartis, Sanofi Genzyme and TG Therapeutics.. |
| David W. Dodick, MD, FAAN | Dr. Dodick has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with David W. Dodick reports the following conflicts: Personal fees: Amgen, Association of Translational Medicine, University Health Network, Daniel Edelman Inc., Autonomic technologies, Axsome, Aural Analytics, Allergan, Alder, Biohaven, Charleston Laboratories, Dr Reddy's Laboratories/Promius, Electrocore LLC, Eli Lilly, eNeura, Neurolief, Novartis, Ipsen, Impel, Satsuma, Supernus, Sun Pharma (India), Theranica, Teva, Vedanta, WL Gore, Nocira, PSL Group Services, University of British Columbia, , XoC, Zosano, ZP Opco, Foresite Capital, Oppenheimer. CME fees or Royalty payments Healthlogix, Medicom Worldwide, Medlogix Communications, Mednet, Miller Medical, PeerView, WebMD Health/Medscape, Chameleon, Academy for Continued Healthcare Learning, Universal meeting management, Haymarket , Global Scientific Communications, Global Life Sciences, Global Access Meetings, UpToDate (Elsevier), Oxford University Press, Cambridge University Press, Wolters Kluwer Health; Stock options: Aural analytics, Healint, Theranica, Second Opinon/Mobile Health, Epien, GBS/Nocira, Matterhorn/Ontologics, King-Devick Technologies. Consulting without fee: Aural Analytics, Healint, Second Opinion/Mobile Health, Epien; Board of Directors: Epien, Matterhorn/Ontologics, King-Devick Technologies. Patent :17189376.1-1466:vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis without fee. Professional society fees or reimbursement for travel: American Academy of Neurology, American Brain Foundation, American Headache Society, American Migraine Foundation, International Headache Society, Canadian Headache Society. Other: Use agreement through employer: Myndshft. Dr. Dodick has received compensation for serving on the Board of Directors of Stock options: Aural analytics, Healint, Theranica, Second Opinon/Mobile Health, Epien, GBS/Nocira, Matterhorn/Ontologics, King-Devick Technologies. Consulting without fee: Aural Analytics, Healint, Second Opinion/Mobile Health, Epien; Board of Directors: Epien, Matterhorn/Ontologics, King-Devick Technologies. Dr. Dodick holds stock and/or stock options in Stock options: Aural analytics, Healint, Theranica, Second Opinon/Mobile Health, Epien, GBS/Nocira, Matterhorn/Ontologics, King-Devick Technologies. Consulting without fee: Aural Analytics, Healint, Second Opinion/Mobile Health, Epien; Board of Directors: Epien, Matterhorn/Ontologics, King-Devick Technologies. |
| Josep Gamez, MD, PhD | Dr. Gamez has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Minoryx, Italfarmaco, Octapharma AG, and CSL Behring. |
| Vinai Gondi | Dr. Gondi has nothing to disclose. |
| Mark L. Moster, MD, FAAN | Dr. Moster has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Gensight and Sanofi Genzyme. Dr. Moster has received research support from GenSight. |
| Susan Rowell, MD, MCR | Dr. Rowell has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Portola Pharmaceuticals. Dr. Rowell has received research support from NIH, DOD. |
| Tanya Simuni, MD | Dr. Simuni has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acadia, Adamas, Teva, Abbvie, Anavex, Allergan, Accorda, Neuroderm, Photopharmics, Revance, Sanofi, Sunovion, Voyager, US World Meds, and the Michael J. Fox Foundation, Denali,Neurocrine, Takeda, Dr. Simuni has received research support from Biogen, Roche, Neuroderm, Sanofi, Sun Pharma, NINDS, the Michael J. Fox Foundation, and the Parkinson Foundation. |
| Jeff D. Williamson | Dr. Williamson has nothing to disclose. |
| Start Time | Pub. | Title | Presenter |
|---|---|---|---|
| 000 | A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Final study results |
Tanya Simuni Disclosure: Dr. Simuni has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acadia, Adamas, Teva, Abbvie, Anavex, Allergan, Accorda, Neuroderm, Photopharmics, Revance, Sanofi, Sunovion, Voyager, US World Meds, and the Michael J. Fox Foundation, Denali,Neurocrine, Takeda, Dr. Simuni has received research support from Biogen, Roche, Neuroderm, Sanofi, Sun Pharma, NINDS, the Michael J. Fox Foundation, and the Parkinson Foundation.
|